KLRA — Kailera Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2096997 ·
Last close
$12.20
Market Cap
$1.58B
52W High
$28.23
52W Low
$9.76
ADV30
1,032,429
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -106,336,000 -95,665,000 1,082,178,000 106,537,000 51,062,000
Jun 2026 0 — -121,373,000 -111,307,000 1,211,416,000 130,301,000 92,952,000
Mar 2026 0 — -84,660,000 -78,865,000 624,756,000 111,826,000 1,056,844,000
Dec 2025 0 — -67,123,000 -62,402,000 692,294,000 160,267,000 1,048,752,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-325,585,000
Investing CF
$-827,818,000
Financing CF
$1,162,026,000
CapEx
$-1,645,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.83
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-654,505,000
Inventory
—
Receivables
$6,260,000
ST Investments
$794,917,000
EBIT TTM
$-379,492,000
Pretax Income TTM
$-348,239,000
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -158,340,000 -148,955,000 692,294,000 1,048,752,000 -356,458,000 -120,210,000
Dec 2024 — — — 178,445,000 397,217,000 -218,772,000 —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$1,211,416,000
Forward EPS
$-4.30

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $11.79 · call volume: 2 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
SRPT Sarepta Therapeutics, Inc. $1.58B $14.77 —
ANIP ANI PHARMACEUTICALS INC $1.59B $69.99 —
NRIX Nurix Therapeutics, Inc. $1.56B $14.24 —
PGEN PRECIGEN, INC. $1.54B $4.29 —
ADRX ADARx Pharmaceuticals, Inc. $1.53B $13.82 —

News headlines (Yahoo Finance, 1h cache)

Kailera Therapeutics to Present at ObesityWeek 2026
2026-11-10 12:00 · Yahoo
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-04 21:05 · Yahoo
Kailera Therapeutics to Participate in November Investor Conferences
2026-11-03 12:15 · Yahoo
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
2026-10-01 10:45 · Yahoo
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
2026-09-30 11:44 · Yahoo
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
2026-09-30 11:00 · Yahoo
Kailera Therapeutics to Participate in September Investor Conferences
2026-09-16 11:00 · Yahoo
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
2026-09-15 04:16 · Yahoo
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
2026-08-18 14:10 · Yahoo
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
2026-08-17 13:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.